ERBB2 and neoplasm: In vitro activation, anti-tumor efficacy and long-term persistence of UniCAR T cells targeted by soluble biotinylated trastuzumab (BT) and HER2-CAR T cells targeted by a trastuzumab derived ScFv were investigated in activation, coculture and rechallenge experiments.